GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2022-03-07| Trials & Approvals

Pfizer’s RSV Vaccine Bags FDA Breakthrough Therapy Status

by Arvind C. Shekhar
Share To

The US FDA has granted a Breakthrough Therapy Designation to Pfizer’s respiratory syncytial virus (RSV) vaccine candidate RSVpreF. RSVpreF is aimed at prevention of RSV-associated lower respiratory tract illness in infants from birth up to six months of age by active immunization of pregnant women.

The Breakthrough Therapy Designation is designed to expedite the development and review of drugs and vaccines that demonstrate substantial improvement over available therapy on a clinically significant endpoint. This decision follows the FDA’s November 2018 decision to grant Fast Track status to RSVpreF. 

Related Article: The Next SuperStar Drug? AbbVie Places its Hope on Skyrizi and Rinvoq

 

Respiratory Syncytial Virus (RSV) a Global Cause of Concern

 

Respiratory syncytial virus (RSV) is estimated to cause 3.4 million hospitalizations and 95,000–150,000 deaths globally. RSV has two major antigenic groups of strains, A and B, and multiple genotypes within the two groups. 

Although the disease burden has made RSV a priority for vaccine development for over 50 years, a vaccine is still unavailable and the medical community is limited to offering only supportive care for those with the illness. 

The RSV genome is composed of 10 genes that encode for 11 proteins. All the RSV proteins have played a role in the design of one or more vaccines, though only two RSV proteins, F and G induce in-vitro neutralizing antibodies.

Related Article: EMA Accepts Application for AstraZeneca’s Anti-RSV Antibody Nirsevimab.

 

RSVpreF and Its Mode of Action

 

During an RSV infection, the F protein (responsible for viral fusion with cellular membranes) goes from the metastable pre-fusion (pre-F) to a stable post-fusion (post-F) state. Research has shown that most of the neutralizing antibodies in humans react against the pre- and not post-fusion form of protein F.

Pfizer’s RSVpreF is based on research which has shown that antibodies specific to the pre-fusion form were highly effective at blocking virus infection, suggesting a prefusion F-based vaccine may confer optimal protection against RSV.

The decision is being viewed as a pivotal next step in the path towards potential regulatory approval for the maternal RSV vaccine candidate, Kathrin U. Jansen, Ph.D., Senior Vice President and Head of Vaccine Research & Development at Pfizer Inc said “If approved by the FDA, this maternal immunization has the potential to be the first vaccine candidate to help protect infants in their vulnerable first months of life from disease caused by this highly-contagious virus. We look forward to our ongoing dialogue with the FDA to accelerate the development of our maternal RSV vaccine candidate.”

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Super Bowl LIX and the Biotech Sector: A New Arena for Engagement
2025-02-09
Major Win – FDA Grants Fast Track Designation to Adicet Bio’s ADI-001 for Lupus Disease
2025-02-07
Easing the Mental Health Burden: How MDMA, Psilocybin, and Other Psychedelics May Open Doors for Treating PTSD, Addiction, and Autism
2025-01-28
LATEST
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
The Fallout of the USAID Funding Freeze: Implications for Global Health and Biopharmaceutical Innovation
2025-02-11
Trump’s Trade War Shake-Up: How U.S. Tariffs Could Disrupt Global Pharma
2025-02-10
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
Scroll to Top